Opioid Antagonist Nalmefene Shows Comparable Effectiveness to Naloxone
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
Read MoreImplanted under the skin, the Naloximeter senses dropping oxygen and sends a warning notification to a mobile app. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone.
Read MoreAn NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of emergency department visits or use of inpatient services related to behavioral health.
Read MoreSurprisingly, naloxone was associated with improved clinical outcomes in both drug-related cardiac arrests and non-drug-related cardiac arrests.
Read MoreThe implantable device, tested in animal models, continuously monitors vital signs and automatically administers naloxone during opioid overdose.
Read MoreThe FDA approved Zurnai, a nalmefene hydrochloride auto-injector, for emergency opioid overdose treatment in individuals aged 12 and older.
Read MoreResearchers say the sheer amount of cannabinoid positivity found during umbilical cord toxicity testing was “pretty astounding.”
Read MoreResearchers have identified a compound from marine fungus that could serve as a safer alternative to opioids.
Read MoreWhen given with morphine, the insomnia drug prevented addiction in mice while maintaining effective pain relief.
Read MoreAdding a newly identified compound makes naloxone more potent and longer lasting, a mouse study shows.
Read MoreA data-driven intervention engaging communities to deploy evidence-based practices did not significantly reduce opioid-related overdose deaths.
Read MoreStarting extended-release naltrexone within five to seven days of seeking treatment improves success rates for opioid addiction compared to the standard 10-15 days, but requires closer medical supervision.
Read MoreThe nasal spray, available at pharmacies without a prescription, is designed to counteract opioid overdoses.
Read MoreA head-to-head pharmacodynamic study examined the ability of both intranasal nalmefene (Opvee) and intranasal naloxone to reverse opioid-induced respiratory depression.
Read MoreEighty-five percent of idiopathic pulmonary fibrosis patients suffer from chronic cough, but low-dose, controlled morphine may offer some relief.
Read MoreAn average of 22 adolescents age 14 to 18 years old died in the US each week in 2022 from drug overdoses, driven by fentanyl in counterfeit pills.
Read MoreThe sensor, which measures heart and breathing rate from patients’ GI tract, could also enable early detection of conditions like asthma and COPD.
Read MoreStarting buprenorphine treatment for opioid use disorder through telehealth increased the likelihood of staying in treatment longer, a federally funded study found.
Read MorePatients prescribed the FDA-recommended dose were significantly more likely to discontinue treatment over 180 days compared to those prescribed a higher dose, an NIH-supported study found.
Read MoreThe US Food and Drug Administration approved a 3-milligram naloxone hydrochloride nasal spray for over-the-counter, nonprescription use for the emergency treatment of known or suspected opioid overdose.
Read MoreThe injectable is approved in both weekly and monthly formulations at varying doses, including lower doses that may be appropriate for those who do not tolerate higher doses.
Read MoreThe nalmefene hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.
Read MoreThe “Eat, Sleep, Console” (ESC) care approach to be more effective than using the Finnegan Neonatal Abstinence Scoring Tool to assess and manage opioid-exposed newborns.
Read MoreThe first year of the COVID pandemic saw significant increases in drug overdose deaths and gap in between black and white individuals widened.
Read More